Ipilimumab/nivolumabColitis: 2 case reports

被引：0

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1735卷 / 1期

关键词：

D O I：

10.1007/s40278-019-56776-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：160 / 160

相关论文

共 50 条

[31] Ipilimumab/nivolumabColitis, diarrhoea and skin rash: case report
Reactions Weekly, 2019, 1739 (1) : 158 - 158
[32] Infliximab/ipilimumab/nivolumabColitis and lack of efficacy: case report
Reactions Weekly, 2021, 1836 (1) : 419 - 419
[33] Ipilimumab/NivolumabColitis of grade3, adrenal insufficiency of grade 3 and renal dysfunction of grade 2: 3 case reports
Reactions Weekly, 2024, 2035 (1) : 251 - 251
[34] Ipilimumab/nivolumabColitis, hepatitis and acute renal injury: case report
Reactions Weekly, 2024, 2026 (1) : 161 - 161
[35] Ipilimumab/nivolumabSarcoidosis: 2 case reports
Reactions Weekly, 2019, 1744 (1) : 167 - 167
[36] Ipilimumab/nivolumabNeurotoxicity: 2 case reports
Reactions Weekly, 2023, 1965 (1) : 261 - 261
[37] Ipilimumab/nivolumabThyroiditis: 2 case reports
Reactions Weekly, 2023, 1939 (1) : 257 - 257
[38] Ipilimumab/pembrolizumabHypophysitis: 2 case reports
Reactions Weekly, 2018, 1714 (1) : 242 - 242
[39] Ipilimumab/nivolumabPneumonitis: 2 case reports
Reactions Weekly, 2020, 1787 (1) : 305 - 305
[40] Ipilimumab/pembrolizumabHypophysitis: 2 case reports
Reactions Weekly, 2022, 1913 (1) : 268 - 268

← 1 2 3 4 5 →